Integrated Tissue Phenomics and Big Data for Biomarker Discovery and Test Development, New Webinar Hosted by Xtalks
/EINPresswire.com/ -- TORONTO, ON--(Marketwired - June 28, 2016) - During a live presentation on Tuesday, July 19, 2016, industry experts Dr. Ralf Huss, Chief Medical Officer at Definiens AG and Alan Jerusalmi, PhD, Global Head of Professional Services at Definiens Inc., will discuss how Tissue Phenomics represents a novel technique to discover relevant patterns in tissue slides that predict drug response or other clinical outcome. This method is based on digital pathology, image analysis and data mining, and is more and more evolving into a comprehensive big data approach.
Histological phenotypes generally play an essential role in diagnostics, but in particular in oncology there is a growing need for selecting the right patients for the right treatments based on information derived from tissue slides. Oncology is a rapidly evolving field with many new treatment methods being discovered. To finally cope with the complexity of cancer the treatments of cancer patients is becoming increasingly more complex through the availability of those methods and their combinations. As a consequence, diagnostics and the decision, which of those treatments is best for a specific patient at what stage of his or her disease, is certainly not trivial and also requires the analysis of big data.
The benefit of Tissue Phenomics is most obvious for oncology and more specifically -- with respect to companion diagnostics -- for immunotherapy especially checkpoint inhibitors. Quantified morphological structures combined with the local co-existence of certain cell types carry biological meaning. For immunotherapy the characterization of the tumor with its defense mechanisms as well as that of the state and the configuration of the immune cells turns out to be most important. Profiling the individual tumor in a quantitative manner including a big data approach leads to a meaningful response prediction.
There are two live broadcasts scheduled on July 19, at 9am EDT (2pm BST/UK) and 1pm EDT. The speakers will be on hand to take questions from the audience.
To learn more about this complimentary event, visit: Integrated Tissue Phenomics and Big Data for Biomarker Discovery and Test Development
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Image Available: http://www.marketwire.com/library/MwGo/2016/6/27/11G104448/Images/small_logo-740736732461.jpg
Contact:
Dian Razak
Tel: +1 (416) 977-6555 ext 352
Email: drazak@xtalks.com

Definiens is the pioneering provider of Tissue Phenomics(R) solutions for biomarker and companion diagnostics development and commercialization
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
